Right. So let’s wait till they have a heart attack before including them on the label . Wait ...30 % of first MI’s are fatal
No worries ... at least we have the other 70 % now covered !!!
Is this is what they are debating ?
Yes ,those Americans with previous events may have a 30 % RRR ... but that does not mean those prescribed statins because they are at risk ... will receive no benefit ?
What’s the risk / benefit analysis here
All CAD patients on statins plus low dose aspirin Drop the aspirin and add the Vascepa That’s about it . Risk of Afib ... look at patient history and make best decision JMO Kiwi
That last line... there is no evidence that ... (basically saying Vascepa label should be for patients on statin with high TG)
Doesn’t all of that possibly change on Monday when evaporate results are shared and then the FDA has evidence that Vascepa actually works better at treating CVD than statins do? (Albeit they work differently). The emphasis placed on statin therapy in the BDs was a bit puzzling ( and I know the statins are SOC)
Market Data 
Markets 
AI
